Coffee intake is associated with longer prostate cancer-specific survival (PCSS) individuals with a certain genotype, according to a study published in European Urology Oncology.
Researchers sought to assess the link associations between coffee intake, caffeine metabolism genotype, and survival in a large, multicenter study of prostate cancer patients. They analyzed 5,727 men with prostate cancer from seven US, Australian, and European studies. The data comprised CYP1A2 -163C>A rs762551 single-nucleotide variants associated with caffeine metabolism, coffee intake, and over six months of follow-up.
According to the results, high coffee intake was correlated with longer PCSS, although results were not statistically significant, the researchers noted. The researchers further noted that the group with clinically localized disease, high coffee intake was associated with longer PCSS (HR 0.66, 95% CI 0.44-0.98; p = 0.040), with comparable results for the group with advanced disease (HR 0.92, 95% CI 0.69-1.23; p = 0.6). The researchers concluded that “it is likely that coffee intake is associated with longer prostate cancer-specific survival in certain groups, but more research is needed to fully understand which men may benefit and why.”